Edward Tenthoff
Stock Analyst at Piper Sandler
(3.20)
# 1,118
Out of 5,113 analysts
193
Total ratings
43.78%
Success rate
2.91%
Average return
Main Sectors:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Maintains: Overweight | $2 → $4 | $2.42 | +65.29% | 9 | Jan 20, 2026 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Overweight | $28 → $37 | $22.84 | +62.00% | 4 | Jan 14, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | $100 → $110 | $67.05 | +64.06% | 14 | Jan 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintains: Overweight | $6 → $8 | $2.05 | +290.24% | 1 | Jan 9, 2026 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $20 → $45 | $23.20 | +93.97% | 2 | Dec 10, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $98 → $125 | $69.93 | +78.75% | 5 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $16 → $23 | $10.75 | +113.95% | 6 | Dec 8, 2025 | |
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $48.71 | +29.34% | 13 | Nov 21, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.51 | +297.35% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $357.98 | +36.60% | 15 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $6.59 | +82.09% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $12 | $4.01 | +199.25% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $15 | $11.90 | +26.05% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $55.52 | +89.12% | 7 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 | $15.05 | +32.89% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.34 | +422.39% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $12.89 | +8.61% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $18.00 | +166.67% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $18.38 | +30.58% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $19.01 | +310.31% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $12.78 | +134.74% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $2.98 | +2,081.21% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.01 | +1,880.20% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.32 | +127.27% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.38 | +689.47% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.21 | +395.87% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.98 | +152.53% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $57.63 | +330.33% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.70 | +2,332.43% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $15.05 | +1,096.01% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $18.54 | +137.32% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $6.95 | +432.37% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40,439,520 → $11,721,600 | $8.98 | +130,529,966.82% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $814.74 | -56.55% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $468.41 | -31.04% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $25 | $10.31 | +142.48% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $44.27 | -18.68% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $2.10 | +1,090.48% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.72 | +20,733.33% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $0.48 | +2,905,163.16% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $753.55 | - | 11 | Feb 13, 2017 |
Century Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $2 → $4
Current: $2.42
Upside: +65.29%
Monte Rosa Therapeutics
Jan 14, 2026
Reiterates: Overweight
Price Target: $28 → $37
Current: $22.84
Upside: +62.00%
Arrowhead Pharmaceuticals
Jan 13, 2026
Reiterates: Overweight
Price Target: $100 → $110
Current: $67.05
Upside: +64.06%
Acrivon Therapeutics
Jan 9, 2026
Maintains: Overweight
Price Target: $6 → $8
Current: $2.05
Upside: +290.24%
Capricor Therapeutics
Dec 10, 2025
Reiterates: Overweight
Price Target: $20 → $45
Current: $23.20
Upside: +93.97%
Kymera Therapeutics
Dec 9, 2025
Reiterates: Overweight
Price Target: $98 → $125
Current: $69.93
Upside: +78.75%
Fulcrum Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $16 → $23
Current: $10.75
Upside: +113.95%
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $48.71
Upside: +29.34%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.51
Upside: +297.35%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $357.98
Upside: +36.60%
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $6.59
Upside: +82.09%
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $4.01
Upside: +199.25%
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $11.90
Upside: +26.05%
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $55.52
Upside: +89.12%
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $15.05
Upside: +32.89%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.34
Upside: +422.39%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $12.89
Upside: +8.61%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $18.00
Upside: +166.67%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $18.38
Upside: +30.58%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $19.01
Upside: +310.31%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $12.78
Upside: +134.74%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $2.98
Upside: +2,081.21%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.01
Upside: +1,880.20%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.32
Upside: +127.27%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.38
Upside: +689.47%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.21
Upside: +395.87%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.98
Upside: +152.53%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $57.63
Upside: +330.33%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.70
Upside: +2,332.43%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $15.05
Upside: +1,096.01%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $18.54
Upside: +137.32%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $6.95
Upside: +432.37%
May 13, 2022
Maintains: Overweight
Price Target: $40,439,520 → $11,721,600
Current: $8.98
Upside: +130,529,966.82%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $814.74
Upside: -56.55%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $468.41
Upside: -31.04%
May 7, 2021
Downgrades: Neutral
Price Target: $80 → $25
Current: $10.31
Upside: +142.48%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $44.27
Upside: -18.68%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $2.10
Upside: +1,090.48%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.72
Upside: +20,733.33%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $0.48
Upside: +2,905,163.16%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $753.55
Upside: -